⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Official Title: A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM

Study ID: NCT03565991

Interventions

Avelumab
Talazoparib

Study Description

Brief Summary: Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.

Detailed Description: Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against programmed death ligand 1 (PD-L1). Avelumab selectively binds to PD-L1 and competitively blocks its interaction with programmed death receptor 1 (PD-1), thereby interfering with this key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single agent and in combination with other anti cancer therapies in patients with locally advanced or metastatic solid tumors and various hematological malignancies. Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair, replication, and transcription. Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors with a BReast CAncer susceptibility gene (BRCA)1, or BRCA2, or ataxia telangiectasia mutated (ATM) gene defect.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Stanford Cancer Center, Palo Alto, California, United States

Stanford Women's Cancer Center, Palo Alto, California, United States

Stanford Healthcare, Stanford, California, United States

Stanford University School of Medicine, Stanford, California, United States

Atlanta Cancer Care -Alpharetta, Alpharetta, Georgia, United States

Northside Hospital, Inc. - GCS/Athens, Athens, Georgia, United States

Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States

Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States

Northside Hospital, Inc. - Central Research Department, Atlanta, Georgia, United States

Northside Hospital, Inc. - GCS/Northside, Atlanta, Georgia, United States

Northside Hospital, Inc. - GCS/Canton, Canton, Georgia, United States

Atlanta Cancer Care - Cumming, Cumming, Georgia, United States

Atlanta Cancer Care - Decatur, Decatur, Georgia, United States

Northside Hospital, Inc.-GCS/Stemmer, Decatur, Georgia, United States

Atlanta Cancer Care - Stockbridge, Jonesboro, Georgia, United States

Northside Hospital, Inc.-GCS/Macon, Macon, Georgia, United States

Northside Hospital, Inc.-GCS/Kennestone, Marietta, Georgia, United States

Ochsner Clinic Foundation, New Orleans, Louisiana, United States

Brigham and Women's Hospital, Boston, Massachusetts, United States

Dana Farber Cancer institute, Boston, Massachusetts, United States

Siteman Cancer Center - West County, Creve Coeur, Missouri, United States

Barnes-Jewish Hospital, Saint Louis, Missouri, United States

Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Siteman Cancer Center - South County, Saint Louis, Missouri, United States

Siteman Cancer Center - North County, Saint Louis, Missouri, United States

Siteman Cancer Center - St.Peters, Saint Peters, Missouri, United States

Memorial Sloan Kettering Cancer Center- Monmouth, Middletown, New Jersey, United States

Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States

Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City, New York, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

Laura and Isaac Perlmutter Cancer Center, New York, New York, United States

NY Investigational Pharmacy, New York, New York, United States

NYU Langone Medical Center, New York, New York, United States

NYU Langone Radiology - 32nd Street, New York, New York, United States

NYU Langone Radiology Ambulatory Care Center East 41st Street, New York, New York, United States

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York, United States

Rockefeller Outpatient Center, New York, New York, United States

Rockefeller Outpatient Pavilion (53rd Street), New York, New York, United States

Evelyn H. Lauder Breast and Imaging Center, New York, New York, United States

Memorial Hospital, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

White Plains Hospital, White Plains, New York, United States

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

The Ohio State University, Columbus, Ohio, United States

Stephanie Spielman Comprehensive Breast Cancer, Columbus, Ohio, United States

Martha Morehouse Medical Plaza, Columbus, Ohio, United States

OSU Gynecologic Oncology at Mill Run, Hilliard, Ohio, United States

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

Hospital of the University of Pennsylvania/Penn Investigational Drug Services, Philadelphia, Pennsylvania, United States

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Penn IDS Central, Philadelphia, Pennsylvania, United States

Magee-Women's Hospital Women's Cancer Center, Pittsburgh, Pennsylvania, United States

UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States

The Sarah Cannon Research Institute, Chattanooga, Tennessee, United States

Tennessee Oncology, PLLC, Cleveland, Tennessee, United States

Tennessee Oncology, PLLC, Dickson, Tennessee, United States

Tennessee Oncology, PLLC, Franklin, Tennessee, United States

Tennessee Oncology, PLLC, Gallatin, Tennessee, United States

Tennessee Oncology, PLLC, Hermitage, Tennessee, United States

Tennessee Oncology, PLLC, Lebanon, Tennessee, United States

Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

The Sarah Cannon Research Institute, Nashville, Tennessee, United States

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States

Tennessee Oncology, PLLC, Smyrna, Tennessee, United States

The University of Texas, Houston, Texas, United States

Institut Jules Bordet, Brussels, , Belgium

UZ Brussel, Brussel, , Belgium

Universitair Ziekenhuis Antwerpen, Edegem, , Belgium

Rigshospitalet, Copenhagen, , Denmark

Odense University Hospital, Odense C, , Denmark

Centre Jean Perrin, Clermont Ferrand, , France

Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, , France

Institut Regional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier Cedex 5, , France

Presidio AO-U, Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Torette Di Ancona, AN, Italy

IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

Azienda Socio-Sanitaria Territoriale Monza, Ospedale San Gerardo, Monza, MB, Italy

Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, MI, Italy

Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Milano, MI, Italy

Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori, Napoli, , Italy

Azienda Policlinico Umberto I, Universita La Sapienza, Oncologia B, Roma, , Italy

Fondazione Policlinico Universitario Agostino Gemelli Unità di Farmacologia Clinica, Roma, , Italy

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

Amsterdam University Medical Centre, location VUmc, Amsterdam, Noord Holland, Netherlands

Erasmus Universitair Medisch Centrum, Rotterdam, Zuid-holland, Netherlands

Hospital Universitario Vall d'Hebron, Barcelona, , Spain

H.G.U. Gregorio Maranon, Madrid, , Spain

Clinica Universidad de Navarra, Madrid, , Spain

H.U. Fundación Jiménez Díaz, Madrid, , Spain

Hospital Universitario Virgen de Valme, Sevilla, , Spain

Barts Health NHS Trust, St Bartholomew's Hospital, London, , United Kingdom

Sarah Cannon Research Institute UK, London, , United Kingdom

Contact Details

Name: Pfizer CT.gov Call Center

Affiliation: Pfizer

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: